Obesity and overweight. Obesity, unspecified
Conditions
Interventions
Intervention 1: Intervention group: the treatment group will receive 2 pearls of Nigella sativa per day after lunch and dinner, that each pearl contain 1000 ml of nigella sativa for 2 periods of 2 mon
the pearls are produced by Barij Co. Intervention 2: Control group: the placebo group will receive 2 pearls per day , that each pear contain 1000 ml of placebo for 2 periods of 2 months
one month of washout period will be performed between the 2 periods. placebo will be the oral paraffin.
Sponsors
Yazd University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
25 Years to 55 Years
Inclusion criteria
Inclusion criteria: Obese women whose overweight and obesity were defined according to WHO criteria. The BMI range of participants should be between 27 to 35 kg/m2. Age ranges should be 25 to 55 years old. Healthy overweight and obese women will be interred to the study.
Exclusion criteria
Exclusion criteria: Having replacement treatments like Hormone or supplemental vitamins or weight loss drugs; tobacco and alcohol use chronic or acute inflammatory disease ; heart valve disease ; short bowel syndrome ; allergies individuals with low immune system (autoimmune diseases) pregnancy and lactation consuming less than 40% of Nigella sativa or placebo supplements. individuals who had allergy to the nigella sativa supplements.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Alteration in adipogenesis related gene sequence. Timepoint: Four times; at the beginning and the end of the first 2-month trial and at beginning and the end of the second 2-month trial. Method of measurement: centrifuge.;Liver enzyme, alanine aminotransferase (ALT). Timepoint: 4 times; at the initiation and the end of the first 2-month trial and at the initiation and the end of the second 2-month trial. Method of measurement: Assay Kits (Pars Azmoon Co.).;Lipid profile. Timepoint: 4 times; at the initiation and the end of the first 2-month trial and at the initiation and the end of the second 2-month trial. Method of measurement: Assay kits (Padgin Teb Co.).;Liver enzyme, Aspartate aminotransferase. Timepoint: 4 times; at the initiation and the end of the first 2-month trial and at the initiation and the end of the second 2-month trial. Method of measurement: Assay Kits (Pars Azmoon Co.).;Liver enzyme, Alkaline phosphatase (ALK). Timepoint: 4 times; at the initiation and the end of the first 2-month trial and at the initiation and the end of the second 2-month trial. Method of measurement: Assay Kits (Pars Azmoon Co.). | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood Pressure. Timepoint: 4 times; at the initiation and the end of the first 2-month trial and at the initiation and the end of the second 2-month trial. Method of measurement: Mercury barometer.;Anthropometric measurments. Timepoint: 4 times; at the initiation and the end of the first 2-month trial and at the initiation and the end of the second 2-month trial. Method of measurement: digital anthropometric scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAzadeh Nadjarzadeh
Yazd University of Medical Sciences
Outcome results
None listed